TPDB08712

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 3.1 µg/mL

Target

Target Organism S. typhimurium LT2 and 1102

Source & Reference

Database Source dbAMP DRAMP

Other

Source Activity Label	Source Definition
Antibacterial	dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. au

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 6.3 µg/mL

Target

Target Organism Escherichia coli K12

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 3.1-6.3 µg/mL

Target

Target Organism S. Minnesota 1114W or R595

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

e against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml).

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus aureus 209P or ATCC 25923

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

g/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881

Evidence 5 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 6.3 µg/mL

Target

Target Organism Candida albicans M9

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MI

Evidence 6 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 4.07 µM

Target

Target Organism Candida albicans SC5314

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

, Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22

Evidence 7 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 4.07 µM

Target

Target Organism C. krusei IFM56881

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

23 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al.,

Evidence 8 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 1.02 µM

Target

Target Organism C. neoformans H99

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

ns M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by

Evidence 9 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 1.02 µM

Target

Target Organism C. parapsilosis ATCC22019

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

s SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by binding to gp120 and CD4.

Evidence 10 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 3.1 µg/mL

Target

Target Organism S. typhimurium LT2 and 1102

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label	Source Definition
Antifungal	dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. au

Evidence 11 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 6.3 µg/mL

Target

Target Organism Escherichia coli K12

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC

Evidence 12 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 3.1-6.3 µg/mL

Target

Target Organism S. Minnesota 1114W or R595

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

e against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml).

Evidence 13 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus aureus 209P or ATCC 25923

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

g/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881

Evidence 14 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 6.3 µg/mL

Target

Target Organism Candida albicans M9

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MI

Evidence 15 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 4.07 µM

Target

Target Organism Candida albicans SC5314

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

, Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22

Evidence 16 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 4.07 µM

Target

Target Organism C. krusei IFM56881

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

23 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al.,

Evidence 17 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 1.02 µM

Target

Target Organism C. neoformans H99

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

ns M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by

Evidence 18 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 1.02 µM

Target

Target Organism C. parapsilosis ATCC22019

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

s SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by binding to gp120 and CD4.

Evidence 19 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 3.1 µg/mL

Target

Target Organism S. typhimurium LT2 and 1102

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Source Activity Label	Source Definition
Antiparasitic	DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. au

Evidence 20 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 6.3 µg/mL

Target

Target Organism Escherichia coli K12

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC

Evidence 21 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 3.1-6.3 µg/mL

Target

Target Organism S. Minnesota 1114W or R595

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

e against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml).

Evidence 22 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus aureus 209P or ATCC 25923

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

g/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881

Evidence 23 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 6.3 µg/mL

Target

Target Organism Candida albicans M9

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MI

Evidence 24 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 4.07 µM

Target

Target Organism Candida albicans SC5314

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

, Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22

Evidence 25 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 4.07 µM

Target

Target Organism C. krusei IFM56881

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

23 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al.,

Evidence 26 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 1.02 µM

Target

Target Organism C. neoformans H99

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

ns M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by

Evidence 27 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 1.02 µM

Target

Target Organism C. parapsilosis ATCC22019

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

s SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by binding to gp120 and CD4.

Evidence 28 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 3.1 µg/mL

Target

Target Organism S. typhimurium LT2 and 1102

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Source Activity Label	Source Definition
Antiviral	DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. au

Evidence 29 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 6.3 µg/mL

Target

Target Organism Escherichia coli K12

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

Active against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC

Evidence 30 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 3.1-6.3 µg/mL

Target

Target Organism S. Minnesota 1114W or R595

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

e against Gram- S. typhimurium LT2 and 1102 (MIC 3.1 ug/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml).

Evidence 31 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus aureus 209P or ATCC 25923

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

g/ml), E. coli K12 (MIC 6.3 ug/ml), S. Minnesota 1114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881

Evidence 32 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 6.3 µg/mL

Target

Target Organism Candida albicans M9

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

114W or R595 (MIC 3.1-6.3 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MI

Evidence 33 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 4.07 µM

Target

Target Organism Candida albicans SC5314

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

, Gram+ S. aureus 209P or ATCC 25923 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22

Evidence 34 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 4.07 µM

Target

Target Organism C. krusei IFM56881

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

23 (MIC 6.3 ug/ml), and C. albicans M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al.,

Evidence 35 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 1.02 µM

Target

Target Organism C. neoformans H99

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

ns M9 (MIC 6.3 ug/ml). C. albicans SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by

Evidence 36 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 1.02 µM

Target

Target Organism C. parapsilosis ATCC22019

Source & Reference

Database Source dbAMP 3.0 DRAMP

Other

Evidence Text

s SC5314 (MIC 4.07 uM), C. krusei IFM56881(MIC 4.07 uM), C. neoformans H99 (MIC 1.02 uM), C. parapsilosis ATCC22019 (MIC 1.02 uM) ( Zhang et al., 2022 ). Also, it inhibits HIV by binding to gp120 and CD4.

Evidence 37 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 9.4±1.5 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 9.4±1.5 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Target Cell Human embryonic kidney HEK293T cells

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III. | Mar Drugs | 2018

Evidence 38 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 8.3±0.7 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 8.3±0.7 | µM | target cell: Human embryonic fibroblasts

Target

Target Cell Human embryonic fibroblasts

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III. | Mar Drugs | 2018

Evidence 39 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 14.5±1.6 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 14.5±1.6 | µM | target cell: Human normal astrocytes

Target

Target Cell Human normal astrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III. | Mar Drugs | 2018

Evidence 40 Activity

Activity

Activity Endpoint 45% hemolysis

Detail Source Activity Toxicity

Activity Measurement 100 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

45% hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III. | Mar Drugs | 2018

Evidence 41 Activity

Activity

Activity Endpoint 100% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 21.3 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

100% Hemolysis | 21.3 | µg/mL | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. | Biochemistry | 2000

Evidence 42 Hemolysis

Source & Reference

source APD_complete HemoPI PD_Hemolysis

Database Source APD_complete PD_Hemolysis

Other

Source Activity Label	Source Definition
Hemolysis	APD_complete APD-derived hemolytic peptide annotation.